Pharma BD Deal Intelligence
A platform-validation bet: AstraZeneca paid $240 million upfront toward a $420 million package for five-year exclusive rights to Moderna's mRNA platform across cardiometabolic and oncology targets, with up to 40 candidates selectable — broad optionality, but technical milestones still had to be earned.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AZ obtains exclusive access to select any cardiometabolic mRNA target plus selected oncology targets over five years, with rights to up to 40 development…
AstraZeneca and Moderna announced a multi-year collaboration valued at over $420M for mRNA therapeutics in cardiometabolic disease and cancer — described as…
AstraZeneca's decision to add another $140M equity investment in Moderna in 2016 deepens what began as a 2013 cardiometabolic and oncology mRNA deal,…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca paid $240M upfront + up to $180M technical milestones (total $420M) for 5-year exclusive option on mRNA targets in cardiometabolic plus selected oncology; up to 40 candidate selections plus dev/commercial milestones and royalties.
Assessment window: 5yr post-close.
mRNA therapeutics deliver synthetic messenger RNA into cells to instruct them to manufacture therapeutic proteins or secreted factors in vivo, bypassing recombinant protein manufacturing entirely. The modality is platform-based, applicable across cardiometabolic regeneration (e.g., VEGF-A for ischemic heart disease), metabolic enzyme replacement, and cancer immunotherapy.
When this deal was signed in March 2013, Moderna was a privately held Flagship-incubated pre-clinical biotech and the mRNA therapeutics field was nascent. Direct competitors included CureVac (Germany), BioNTech (Germany), and Translate Bio (then Shire/RaNA Therapeutics) — all working on chemically modified mRNA and lipid nanoparticle delivery. AstraZeneca's $240M upfront plus $180M technical milestones was the largest platform validation any mRNA company had received and arguably bootstrapped Moderna's later expansion into infectious disease vaccines that produced Spikevax. Strategically the deal locked AZ into a five-year exclusive option in cardiometabolic targets plus selected oncology — a significant moat against then-emerging biotech rivals like Alnylam (siRNA) and Isis/Ionis (antisense oligonucleotide) competing for the same protein-modulation use cases. The first clinical asset to emerge (AZD8601, VEGF-A mRNA for heart failure/CABG) reached Phase 2; AstraZeneca subsequently increased its equity stake by $140M in 2016, eventually selling the position for ~$1B post-COVID. The deal is now viewed as one of the most prescient platform plays of the 2010s.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Moderna Therapeutics (this deal) | 2013 | $420M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2013 deals · AstraZeneca PLC deals · Cardiovascular deals